Pharmacoeconomics of chronic kidney disease

A pharmacoeconomic study is a comprehensive scientific and research activity, which should take into account specific characteristics of a research subject as well as nosology based on common methodological approaches of pharmacoeconomics,. The growing significance of the results obtained when performing pharmacoeconomic analysis involves higher requirements to the quality pharmacoeconomic studies, which is largely stipulated by the methodology used. The analysis of the features that have influence when conducting pharmacoeconomic studies has been studied as exemplified by chronic kidney disease. The aspects of the choice of effectiveness criteria for pharmacoeconomic analysis when performing the analysis of «cost-effectiveness», when analyzing «impact on the budget», have been described. It has been shown that the specificity of the analyzed disease is reflected at all stages of pharmacoeconomic studies: elaboration of study design, choice of performance criteria, determination of the research costs profile, implementation of particular methods of pharmacoeconomic analysis, interpretation of the results of pharmacoeconomic evaluation. It was found that pharmacoeconomic analysis of renal replacement therapy in patients with chronic kidney disease is the most specific.

pharmacoeconomics, chronic kidney disease, renal replacement therapy, «cost-effectiveness» analysis, «impact on the budget» analysis, performance criteria, cost analysis, methodology of pharmacoeconomic analysis, фармакоэкономика, хроническая болезнь почек, заместительная почечная терапия, анализ «затраты-эффективность», анализ «влияния на бюджет», критерии эффективности, анализ затрат, методология фармакоэкономического анализа

1. Yagudina RI, Kulikov AYu, Serpik VG, Protsenko MV, Goloenko NG. Development of pharmacoeconomic analysis according to current requirements of health care system in the Russian Federation. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya 2014; (3): 56–61 (in Russian).

2. Shestakova MV. The modern concept of «chronic kidney disease»: diagnostic methods, clinical significance. Saharny diabet 2008; (2): 4–7 (in Russian).

3. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. American Journal of Kidney Diseases 2002; (39): 2.

4. Smirnov AV. National guidelines. Chronic kidney disease: the basic principles of screening, diagnosis, prevention and treatment approaches. Moscow; 2011 (in Russian).

5. Habriev RU, Kulikov AYu, Arinina EE. Methodological basics of pharmacoeconomic analysis. Moscow: Meditsina; 2011 (in Russian).

6. Kuzmin OB. Chronic kidney disease and cardiovascular system. Nefrologiya 2007; 11(1): 28–37 (in Russian).

7. Practical recommendations KDIGO on diagnosis, prevention and treatment of mineral and bone disorders in chronic kidney disease. Summary of recommendations. Nefrologiya 2011; 15(1): 88–95 (in Russian).

8. Maslova OV, Suntsov YuI, Shestakova MV, Kazakov IV. The prevalence of renal disease in diabetes mellitus type 1 and 2 in the Russian Federation. Saharny diabet 2009; (4): 48¬–51 (in Russian).

9. Yagudina RI, Serpik VG. On the possibility of combining the analysis of the «impact on the budget» and the analysis of «cost-effectiveness» – the creation of «3D» pharmacoeconomic model. Farmakoekonomika: teoriya i praktika 2014; 2(3): 4–8 (in Russian).

10. Yagudina RI, Kulikov AYu, Serpik VG, Abdrashitova GT. The economic burden of chronic kidney disease in the Russian Federation. Farmakoekonomika: teoriya i praktika 2014; 2(4): 34–39 (in Russian).